No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XERS Xeris Pharmaceuticals
- 1.740
- -0.020-1.14%
Close Apr 19 16:00 ET
- 1.730
- -0.010-0.57%
Post 18:56 ET
244.39MMarket Cap-3866P/E (TTM)
1.780High1.690Low2.01MVolume1.760Open1.760Pre Close3.47MTurnover1.50%Turnover RatioLossP/E (Static)140.45MShares3.26052wk High-36.25P/B233.49MFloat Cap1.46052wk Low--Dividend TTM134.19MShs Float27.983Historical High--Div YieldTTM5.11%Amplitude0.970Historical Low1.724Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Top Owners Are Retail Investors With 51% Stake, While 45% Is Held by Institutions
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today
Xeris Gains as Oppenheimer Highlights Drug Technology
Xeris Biopharma Initiated at Outperform by Oppenheimer
Xeris Biopharma Initiated at Outperform by Oppenheimer
Express News | Oppenheimer Initiates Coverage On Xeris Biopharma Holdings With Outperform Rating, Announces Price Target of $5
Comments
Despite Xeris Biopharma Holdings' strong performance, its growth projections are subdued compared to the industry. This could lead to a share price decline if the P/S ratio falls to align with the growth outlook.
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 29% But Its Business Is Yet to Catch Up
News
$Xeris Pharmaceuticals(XERS.US$Moomoo 24/7· 1 min ago1min
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
Xeris Biopharma's poor revenue growth forecast and subpar industry growth dampen optimism around the stock’s future. Despite a share price surge, market sentiment remains pessimistic and strong future increases appear unlikely.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg